Revolution Medicines (RVMDW) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $8.79, +4.64% vs the prior close of $8.40.
- Volume 8.74K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RVMDW jumps 4.6% to $8.79. Closed at $8.79, +4.64% vs the prior close of $8.40. Day range $8.29–$8.79, opened at $0.39.
RVMDW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — RVMDW jumps 4.6% to $8.79
- Closed at $8.79, +4.64% vs the prior close of $8.40. Day range $8.29–$8.79, opened at $0.39.
- Volume was 8.74K shares, 0.1x its 50-day average of 69.53K — lighter than usual.
- 52-week range $8.17–$9.00; today's close sits at 75% of that range, 2.3% below the 52-week high.
RVMDW bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Latest fiscal-year net income: loss of $1.13B.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Share count up 14.7% in a year (dilution).
- High volatility: average daily move of 4.6% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
RVMDW latest news & SEC filings
Every SEC filing by or about RVMDW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sandler Alan B. converted options/RSUs into 6,000 shares at $58.84 (≈$353.04K) on Sep 29, 2026; now holds 58,868
- Sandler Alan B. sold 2,200 shares at $200.82 (≈$441.80K) on Sep 29, 2026; now holds 56,668
- Sandler Alan B. sold 1,609 shares at $201.72 (≈$324.57K) on Sep 29, 2026; now holds 55,059
- Sandler Alan B. sold 1,000 shares at $202.81 (≈$202.81K) on Sep 29, 2026; now holds 54,059
- Sandler Alan B. sold 1,199 shares at $203.91 (≈$244.48K) on Sep 29, 2026; now holds 52,860
- Sandler Alan B. sold 301 shares at $204.72 (≈$61.62K) on Sep 29, 2026; now holds 52,559
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cislini Jeff sold 765 shares at $207.32 (≈$158.60K) on Sep 25, 2026; now holds 51,776
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mancini Anthony sold 587 shares at $200.00 (≈$117.40K) on Sep 24, 2026; now holds 39,765
- Mancini Anthony converted options/RSUs into 3,121 shares at $33.62 (≈$104.93K) on Sep 25, 2026; now holds 42,886
- Mancini Anthony sold 3,121 shares at $200.54 (≈$625.89K) on Sep 25, 2026; now holds 39,765
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Anderson Elizabeth M converted options/RSUs into 5,070 shares at $1.12 (≈$5.68K) on Sep 22, 2026; now holds 14,476
- Anderson Elizabeth M sold 910 shares at $191.85 (≈$174.59K) on Sep 22, 2026; now holds 13,566
- Anderson Elizabeth M sold 4,985 shares at $192.54 (≈$959.81K) on Sep 22, 2026; now holds 8,581
- Anderson Elizabeth M sold 2,648 shares at $193.44 (≈$512.23K) on Sep 22, 2026; now holds 5,933
- Anderson Elizabeth M sold 1,500 shares at $194.59 (≈$291.88K) on Sep 22, 2026; now holds 4,433
- Anderson Elizabeth M sold 100 shares at $195.15 (≈$19.52K) on Sep 22, 2026; now holds 4,333
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$644.37M (prior year -$247.79M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$3.06 (prior year -$1.31) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RVMDW
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.64% (largest 4.6%). That is a volatile stock.
- Liquidity: about 39.14K shares (≈$344.01K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.79 vs a range of $8.17–$9.00 (75% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jeff Cislini sold 765 shares on Sep 25, 2026.
- Latest filings: 8-K Oct 13, 2026; 8-K Sep 1, 2026; 8-K Aug 26, 2026.
- Share count: 214.34M shares outstanding (Jul 31, 2026), +14.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
RVMDW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 0.39 | 8.79 | 8.29 | 8.79 | 8.74K |
| Oct 16, 2026 | 0.39 | 9.00 | 8.17 | 8.40 | 69.53K |
About Revolution Medicines
Revolution Medicines (RVMDW) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in REDWOOD CITY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1628171.
RVMDW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Elizabeth M Anderson | Director | Sep 24, 2026 |
| Flavia Borellini | Director | Jun 23, 2026 |
| Alexis Borisy | Director | Jun 23, 2026 |
| Frank Clyburn | Director | Jun 23, 2026 |
| Mark A Goldsmith | See Remarks | Sep 18, 2026 |
| Sandra Horning | Director | Jun 23, 2026 |
| Lorence H. Kim | Director | Sep 10, 2026 |
| Sushil Patel | Director | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jack Anders | Chief Financial Officer | Sep 18, 2026 |
| Jeff Cislini | SVP & General Counsel | Sep 29, 2026 |
| Mark A Goldsmith | See Remarks | Sep 18, 2026 |
| Margaret A Horn | Chief Operating Officer | Sep 18, 2026 |
| Stephen Michael Kelsey | See Remarks | Sep 18, 2026 |
| Anthony Mancini | See Remarks | Sep 28, 2026 |
| Alan B. Sandler | Chief Development Officer | Sep 18, 2026 |
| Xiaolin Wang | See Remarks | Mar 19, 2026 |
| Lin Wei | Chief Medical Officer | Mar 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 22, 2026 | Elizabeth M Anderson | Sale | 100 | $195.15 |
| Sep 22, 2026 | Elizabeth M Anderson | Sale | 2,648 | $193.44 |
| Sep 22, 2026 | Elizabeth M Anderson | Sale | 4,985 | $192.54 |
RVMDW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-1.13B | -5.95 | $-897.74M |
| Dec 31, 2024 | $0 | $-600.09M | -3.58 | $-557.44M |
| Dec 31, 2023 | $11.58M | $-436.37M | -3.86 | $-350.57M |
| Dec 31, 2022 | $35.38M | $-248.71M | -3.08 | $-224.40M |
| Dec 31, 2021 | $29.39M | $-187.09M | -2.57 | $-147.18M |
Latest balance sheet: total assets $4.32B, total liabilities $1.72B, cash $815.43M (as of Jun 30, 2026).
RVMDW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | — |
| May 6, 2026 | 8-K Item 2.02 (results) | — |
| Feb 25, 2026 | 8-K Item 2.02 (results) | — |
| Nov 5, 2025 | 8-K Item 2.02 (results) | — |
| Aug 6, 2025 | 8-K Item 2.02 (results) | — |
| May 7, 2025 | 8-K Item 2.02 (results) | — |
| Feb 26, 2025 | 8-K Item 2.02 (results) | — |
| Nov 6, 2024 | 8-K Item 2.02 (results) | — |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
| Jan 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)Repligen (RGEN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on RVMDW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.